According to a recently published report by Brisk Insights, the Global Opioid Induced Constipation (OIC) Drugs Market is expected to grow at the CAGR of 4.6% during 2017-2025. The global opioid induced constipation drugs market is segmented on the basis of drug type, prescription type and geography. The report on global opioid induced constipation drugs market (by drug type, prescription type and geography) provides a detailed overview and predictive analysis of the market.
Full report available on Opioid Induced Constipation (OIC) Drugs Market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/opioid-induced-constipation-drugs-market
The global opioid induced constipation (OIC) drugs market is anticipated to grow significantly during the forecast period due to rising opioid prescription for non-cancer pain in the previous decade. It is observed that Methylnaltrexone bromide, lubiprostone and naloxegol drugs are widely accepted in market for treatment of OIC. Among these, methylnaltrexone bromide currently held largest market share and is expected to show significant growth during the forecast period because it provides good relief from constipation in terminally ill patients who do not respond to laxatives. Currently, Naloxegol is widely accepted OIC drugs for the treatment of constipation and is expected to grow at highest CAGR during forecast period due it relieve constipation without reducing the pain relieving effects of opioids is the major factor would fuel the growth of Naloxegol market during forecast period. Promising pipeline molecules such as Naldemedine, Elobixibat and Dolcanatide expected to drive the growth of OIC drugs market during forecast period. Currently, North America and Europe is expected to be the largest regional market for OIC drugs worldwide due to higher cost of treatment, upsurge in funding by government and adoption of novel medication are influencing the growth of OIC drugs market in North America and Europe.
Request Sample: http://www.briskinsights.com/sample-request/586
Scope of the report
1. Global OIC Drugs Market, by Drug Type, 2015–2025 ($ Million)
1.1. Methylnaltrexone Bromide
1.4. Pipeline Drug Analysis: Naldemedine, Elobixibat and Dolcanatide
2. Global OIC Drugs Market, by Prescription Type, 2015–2025 ($ Million)
2.1. Prescribed Drugs
2.2. Over the Counter Drugs
3. Global OIC Drugs Market, by Geography, 2015-2025 ($ Million)
3.1. North America
3.2.4. Rest of Europe
3.3. Asia Pacific
3.3.3. Rest of Asia Pacific
3.4. Latin America (LATAM)
3.4.3. Rest of Latin America
3.5. Middle East and Africa (MEA)
4. Company Profiles
4.2. Cubist Pharmaceuticals (Adolor Corporation)
4.3. Daiichi Sankyo Co. Ltd.
4.4. Ironwood Pharmaceuticals, Inc.
4.6. Progenics Pharmaceuticals Inc
4.7. Salix Pharmaceuticals Ltd
4.8. Shionogo & Co Ltd
4.9. Sucampo Pharmaceuticals
4.10. Synergy Pharmaceuticals Inc.
About Us :
Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.
Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.
Contact Us :
109 Vernon House
Phone : +448081890034 (UK)
Website : http://www.briskinsights.com/